Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 12/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 3/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | HTR7 | P34969 | 2/20 | 0.44 |
| ▸ | GHSR | Q92847 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1575950 | 0.82 | HTR6 (0.70) | HTR6MEN1KMT2AMAPTHTT | |
| SCHEMBL3153292 | 0.82 | HTR6 (1.00) | HTR6 | |
| SCHEMBL1576289 | 0.77 | HTT (0.54) | HTR6MEN1KMT2AMAPTHTT | |
| SCHEMBL3138888 | 0.77 | HTR6 (0.86) | HTR6HTR1AHTR2AHTR2CHTR7 | |
| SCHEMBL3324172 | 0.75 | HTR6 (0.82) | HTR6 | |
| SCHEMBL3147744 | 0.74 | HTR6 (1.00) | HTR6MEN1KMT2AMAPT | |
| SCHEMBL1576520 | 0.74 | HTR6 (0.54) | HTR6ADRA2AHTR2C | |
| SCHEMBL4968171 | 0.73 | HTR6 (0.84) | HTR6HTR2A | |
| SCHEMBL26508353 | 0.68 | HTR2A (0.63) | HTR6HTR1ADRD2HTR2A | |
| SCHEMBL3147704 | 0.67 | HTR6 (1.00) | HTR6HTR1AHTR2AHTR2CHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081600-B1 | Combination of the NMDA- receptor ligand memantine and a compound with 5-HT6 receptor affinity | ESTEVE LABOR DR (ES) | 2012-12-05 | — | — | EP | claimed |
| EP-2308871-A1 | Substituted indole compounds and their use as 5-HT6 receptor modulators | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-04-13 | — | — | EP | claimed |
| US-20090264457-A1 | Combination of at least two 5HT6-Ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-10-22 | — | — | US | claimed |
| EP-2020230-A1 | Combination of at least two 5-HT6-Ligands | Laboratorios del Dr. Esteve S.A. (ES) | 2009-02-04 | — | — | EP | claimed |
| WO-2009013010-A2 | 5HT6-LIGANDS SUCH AS SULFONAMIDE DERIVATIVES IN DRUG- INDUCED WEIGHT-GAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-01-29 | — | — | WO | claimed |
| EP-2018861-A1 | 5HT6-Ligands such as sulfonamide derivatives in drug-induced weight-gain | Laboratorios del Dr. Esteve S.A. (ES) | 2009-01-28 | — | — | EP | claimed |
| US-20070213326-A1 | SUBSTITUTED INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 RECEPTOR MODULATORS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-09-13 | — | — | US | claimed |
| EP-1786804-A1 | SUBSTITUTED INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 RECEPTOR MODULATORS | Laboratorios del Dr. Esteve S.A. (ES) | 2007-05-23 | — | — | EP | claimed |
| WO-2006024535-A1 | SUBSTITUTED INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 RECEPTOR MODULATORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-03-09 | — | — | WO | claimed |
| EP-2081600-B1 | Combination of the NMDA- receptor ligand memantine and a compound with 5-HT6 receptor affinity | ESTEVE LABOR DR (ES) | 2012-12-05 | — | — | EP | disclosed |
| EP-2308871-A1 | Substituted indole compounds and their use as 5-HT6 receptor modulators | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-04-13 | — | — | EP | disclosed |
| US-20100120747-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-05-13 | — | — | US | disclosed |
| US-20100074955-A1 | Combination of NMDA-Receptor Ligand and a Compound With 5-HT6 Receptor Affinity | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-03-25 | — | — | US | disclosed |
| US-20090264457-A1 | Combination of at least two 5HT6-Ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-10-22 | — | — | US | disclosed |
| WO-2007147883-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-12-27 | — | — | WO | disclosed |
| US-20070213326-A1 | SUBSTITUTED INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 RECEPTOR MODULATORS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-09-13 | — | — | US | disclosed |
| US-20070213326-A1 | SUBSTITUTED INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 RECEPTOR MODULATORS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-09-13 | — | — | US | disclosed |
| US-20070213326-A1 | SUBSTITUTED INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 RECEPTOR MODULATORS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-09-13 | — | — | US | disclosed |
| EP-1786804-A1 | SUBSTITUTED INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 RECEPTOR MODULATORS | Laboratorios del Dr. Esteve S.A. (ES) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006024535-A1 | SUBSTITUTED INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 RECEPTOR MODULATORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213326-A1 | SUBSTITUTED INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 RECEPTOR MODULATORS | HTR6, TPH1, TPH2 | HTR6 1/4885MEN1 1818/4885KMT2A 2436/4885 |
| US-20090264457-A1 | Combination of at least two 5HT6-Ligands | HTR6, HTR3B, HTR4 | HTR6 1/4885MEN1 2057/4885KMT2A 592/4885 |
| US-20100120747-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | HTR6, AANAT, ACHE | HTR6 1/4885MEN1 2263/4885KMT2A 1698/4885 |
| US-20100074955-A1 | Combination of NMDA-Receptor Ligand and a Compound With 5-HT6 Receptor Affinity | GRM6, GRIN3B, GRIN3A | HTR6 4/4885MEN1 1091/4885KMT2A 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.